AMG 076
Alternative Names: AMG 071 programme; AMG-076; T 71Latest Information Update: 10 Sep 2008
At a glance
- Originator Amgen
- Class Anorectics; Benzenesulfonates; Cyclohexanecarboxylic acids; Obesity therapies
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 31 Jul 2008 Discontinued - Phase-I for Obesity in United Kingdom (PO)
- 13 Aug 2004 Tularik has been acquired and merged into Amgen
- 24 Feb 2004 Preclinical data have been added to the Obesity pharmacodynamics field (JP Morgan Healthcare Conference 14 January 2004)